Market Overview

The Worldwide Netherton Syndrome Industry is Expected to Reach $74 Million by 2027 - ResearchAndMarkets.com

Share:

The "Netherton Syndrome Market Forecast to 2027 - COVID-19 Impact and Global Analysis by Therapy (Keratolytic Agents, Oral and Topical Steroids and Retinoids, Topical Calcineurin Inhibitors, Radiation Therapy, and Biological Therapy), and Geography" report has been added to ResearchAndMarkets.com's offering.

According to this report the global Netherton syndrome market is expected to reach US $74.31 million by 2027 from US $19.57 million in 2019; it is estimated to grow at a CAGR of 20.3% from 2020 to 2027. The report highlights trends prevailing in the global Netherton syndrome market, and the drivers and hindrances pertaining to the market growth.

Netherton syndrome is a rare disorder characterized by trichorrhexis invaginata, atopic diathesis, and ichthyosiform erythroderma. The trichorrhexis invaginata indicates short and brittle hair, atopic diathesis represents susceptibility to allergy problems while ichthyosiform erythroderma encompasses red, inflamed, scaly skin. Netherton syndrome is hereditary as it is an autosomal recessive trait. The disease is majorly caused due to mutations associated with SPINK5 gene. In some cases, although there is no family history of the disease, the syndrome is revealed even when two healthy parents that carry the mutated recessive gene have a child, which receives both copies of the recessive gene.

Based on therapy, the global Netherton syndrome market is segmented into keratolytic agents, oral and topical steroids and retinoids, topical calcineurin inhibitors, biological therapies, and radiation therapies. In 2019, the keratolytic agents segment held the largest share of the global Netherton syndrome market. However, the biological therapy segment is estimated to register the highest CAGR in the market during the forecast period. The growth of the market for the biological therapy segment is attributed to the increasing adoption of biological therapy due to its beneficial treatment outcomes.

Reasons to Buy

  • Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the Netherton syndrome market.
  • Highlights key business priorities in order to assist companies to realign their business strategies.
  • The key findings and recommendations highlight crucial progressive industry trends in the global Netherton syndrome market, thereby allowing players across the value chain to develop effective long-term strategies.
  • Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
  • Scrutinize in-depth global market trends and outlook coupled with the factors driving the market, as well as those hindering it.
  • Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.

Market Dynamics

Drivers

  • Increasing Number of Awareness Campaigns
  • Increasing Drug Launches and Robust Pipeline

Restraint

  • Side-Effects Associated with Netherton Syndrome Drugs

Opportunity

  • Growth Opportunities in Developing Economies

Companies Mentioned

  • Lifemax Laboratories, Inc.
  • Azitra, Inc.
  • Sixera Pharma Ab
  • Dermelix Biotherapeutics
  • Matrisys Bioscience
  • Quoin Pharmaceuticals Ltd.
  • Krystal Biotech, Inc

For more information about this report visit https://www.researchandmarkets.com/r/ppcu9v

View Comments and Join the Discussion!
 
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com